Monday, February 26, 2024
Bexion Pharmaceuticals is a mid-clinical stage biotechnology company developing biologics for the treatment of solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN). Our lead asset BXQ-350 modulates sphingolipid metabolism, increasing the ratio of certain ceramides to S1P in dysregulated cells, allowing for programmed cell death, reduced proliferation, and immune stimulation. The product has also been shown to potentially prevent and treat CIPN.
CEO/Top Company Official
Scott Shively, CEO.
Lead Product in Development
The lead drug candidate, BXQ-350, modulates lysosomal sphingolipid metabolism, inducing tumor cell death and imparting both innate and adaptive immune activity. BXQ-350 is a first-in-class biologic containing the multifunctional, lysosomal activator protein, Saposin C in a nanovesicle formulation.
Development Phase of Primary Product
Number Of Unlicensed Products